专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080096846A1 Arene Ruthenium (ll) Compounds And Their Use In Cancer Therapy 审中-公开
标题翻译：芳钌（II）化合物及其在癌症治疗中的应用
公开(公告)号：US20080096846A1
公开(公告)日：2008-04-24
申请号：US11660627
申请日：2005-08-19
申请人： Abraha Habtemariam , Peter Sadler
发明人： Abraha Habtemariam , Peter Sadler
IPC分类号： A61K31/28 , A61K31/555 , A61K31/655 , A61P35/00 , C07C245/00 , C07F15/00
CPC分类号： C07C211/65 , C07F17/02
摘要： A ruthenium (II) compound of formula (I): or a solvate on prodrug thereof, wherein: R1, R1, R3, R4, R5 and R6 are independently selected from H, C1-7 alkyl, C5-20 aryl, C3-20 heterocyclyl, halo, ester, amido, acyl, sulfo, sulfonamido, ether, thioether, azo, amino, or R1 and R2 together with the ring to which they are attached form a saturated or unsaturated carbocyclic or heterocyclic group containing up to three 3- to 8-membered carbocyclic or heterocyclic rings, wherein each carbocyclic or heterocyclic ring may be fused to one or more other carbocyclic or heterocyclic rings; X is a neutral or negatively charged N- or S-donor ligand; Y is a counterion; in is 0 or 1; q is 1, 2 or 3; C″ is C1-12 alkylene bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are each independently O-donor, N-donor or S-donor ligands, and may be connected to one another. The compounds are used in cancer therapy.
摘要翻译：式（I）的钌（II）化合物或其前药上的溶剂化物，其中：R 1，R 1，R 3， R 4，R 5和R 6独立地选自H，C 1-7烷基，C 5-20芳基，C 3-20杂环基，卤素，酯，酰胺基，酰基，磺基，亚磺酰氨基，醚，硫醚，偶氮，氨基或R 1和R 2与它们所连接的环连同形成饱和或不饱和的含有至多三个3-8元碳环或杂环的碳环或杂环基团，其中每个碳环或杂环可以与一个或多个其它碳环或杂环稠合; X是中性或带负电荷的N-或S-供体配体; Y是反抗; in是0或1; q为1,2或3; C“是与两个A基团结合的C 1-12亚烷基; p为0或1，当p为0时r为1，p为1时r为2; A和B各自独立地为O-供体，N-供体或S-供体配体，并且可以彼此连接。这些化合物用于癌症治疗。

2. 发明申请

US20060258634A1 Ruthenium (II) complexes for the treatment of tumors 失效
标题翻译：用于治疗肿瘤的钌（II）复合物
公开(公告)号：US20060258634A1
公开(公告)日：2006-11-16
申请号：US10554271
申请日：2004-04-29
申请人： Abraha Habtemariam , Peter Sadler
发明人： Abraha Habtemariam , Peter Sadler
IPC分类号： A61K31/555 , A61K31/282 , C07F15/00
CPC分类号： C07F17/02
摘要： Ruthenium (II) compounds of formula (I) are useful in the treatment and/or prevention of cancer.
摘要翻译：式（I）的钌（II）化合物可用于治疗和/或预防癌症。

3. 发明授权

US5807473A Electrolytic water treatment 失效
标题翻译：电解水处理
公开(公告)号：US5807473A
公开(公告)日：1998-09-15
申请号：US722009
申请日：1996-10-10
申请人： Peter Sadler , John Cossich
发明人： Peter Sadler , John Cossich
IPC分类号： C02F1/46 , C02F1/00 , C02F1/461 , C02F1/463 , C02F1/465 , C02F1/467 , C25B15/02
CPC分类号： C02F1/46104 , C02F1/4674 , C02F2001/46157 , C02F2103/42 , C02F2201/4612 , C02F2201/46125 , C02F2201/4613 , C02F2201/46145 , C02F2201/4615 , C02F2209/005 , C02F2209/04 , C02F2209/05 , C02F2209/06 , C02F2303/04
摘要： An apparatus and method for electrolytically treating water which includes one or more reactors. Each reactor has a liquid containing vessel and one or more pairs of electrodes. The electrodes are suitable for a continuous anodic or cathodic operation for treating water. A power source for each reactor provides voltage and current to the electrodes. A controller maintains the voltage and current provided to the electrodes. The duration of each voltage polarity applied to each electrode is substantially the same. The polarity of the voltage to the electrodes is periodically reversed during which there is a period of zero voltage applied to the electrodes between a first polarity and a second polarity. The period of zero voltage results in a substantial reduction of back e.m.f. of the reactor which enhances the service life and efficacy of the electrodes.
摘要翻译： PCT No.PCT / AU95 / 00203 Sec。 371日期：1996年10月10日 102（e）日期1996年10月10日PCT提交1995年4月11日PCT公布。公开号WO95 / 27684 日期1995年10月19日，包括一个或多个反应器的电解水处理装置和方法。每个反应器具有含液体容器和一对或多对电极。这些电极适合用于处理水的连续阳极或阴极操作。每个电抗器的电源为电极提供电压和电流。控制器保持提供给电极的电压和电流。施加到每个电极的每个电压极性的持续时间基本相同。电极的电压的极性周期性地反转，在此期间在第一极性和第二极性之间存在施加到电极的零电压周期。零电压周期大幅度下降。的反应器，其增强了电极的使用寿命和功效。

4. 发明申请

US20070142466A1 PHOTOREACTIVE COMPOUNDS AND COMPOSITIONS 失效
公开(公告)号：US20070142466A1
公开(公告)日：2007-06-21
申请号：US11674183
申请日：2007-02-13
申请人： Peter Sadler , Philippe Muller
发明人： Peter Sadler , Philippe Muller
IPC分类号： A61K31/282 , C07F15/00
CPC分类号： A61K33/24 , A61K31/28 , A61K31/555 , C07F15/0093
摘要： The present invention provides a compound of formula (I): PtIV(N3)2X1X2Y1Y2, wherein X1 and X2 are the same or different and each one is a group NR1R2R3 wherein R1, R2 and R3 are the same or different and each can be any one of H and optionally substituted alkyl, aryl, aralkyl, acyl, cycloalkyl, heterocyclyl, alkenyl, aralkenyl, alkinyl, cycloalkenyl, or X1 and X2 together represent a group R1R2NR4NR1R2 wherein R1 and R2 have the same meaning as before, and R4 represents an optionally substituted divalent, saturated or unsaturated, alkyl chain, an optionally substituted divalent, saturated or unsaturated cycloalkyl or an optionally substituted divalent aryl, or R4 or two or more of R1, R2, R3 and R4 and the respective N atom(s) to which they are linked, represent an optionally substituted heterocyclyl having at least one ring containing said N atom(s); and Y1 and Y2 are the same or different or when cis together represent a divalent moiety Y3, wherein at least one of Y1 and Y2, or Y3, is a substantially labile ligand in the analogous Pt(II) complex without the azide groups, whilst being substantially resistant, in vivo, to hydrolysis and physiological reducing agents. One or more of R1, R2, R3 and R4, may further represent a covalently bonded link to at least one further complex of formula (I) to form a dimer or oligomer, or to a targeting moiety having affinity for a predetermined tissue or cell type.

5. 发明申请

US20060058270A1 Ruthenium anticancer complexes 审中-公开
标题翻译：钌抗癌复合物
公开(公告)号：US20060058270A1
公开(公告)日：2006-03-16
申请号：US10520239
申请日：2003-07-04
申请人： Peter Sadler , Rafael Lainez , Abraba Habtemariam , Michael Melchart , Duncan Jodrell
发明人： Peter Sadler , Rafael Lainez , Abraba Habtemariam , Michael Melchart , Duncan Jodrell
IPC分类号： C07F15/00 , A61K31/655 , A61K31/555 , A61K31/27
CPC分类号： C07F17/02
摘要： Ruthenium (II) compounds of formula (I) are useful in the treatment and/or prevention of cancer, wherein formula (I) is:
摘要翻译：式（I）的钌（II）化合物可用于治疗和/或预防癌症，其中式（I）为：

6. 发明申请

US20050239765A1 Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer 审中-公开
标题翻译：包含用于治疗癌症的含氮配体的半夹心钌（II）化合物
公开(公告)号：US20050239765A1
公开(公告)日：2005-10-27
申请号：US11165372
申请日：2005-06-23
申请人： Robert Morris , Peter Sadler , Haimei Chen , Duncan Jodrell
发明人： Robert Morris , Peter Sadler , Haimei Chen , Duncan Jodrell
IPC分类号： C07D213/81 , A61K31/132 , A61K31/216 , A61K31/275 , A61K31/455 , A61K31/555 , A61K33/24 , A61P35/00 , C07F15/00 , C07F17/02
CPC分类号： A61K31/555 , A61K33/24 , C07F15/0046 , C07F17/02
摘要： Compounds which may be used in the treatment and/or prevention of cancer have the formula (I) wherein: R1, R2, R3, R4, R5 and R6 independently represents H, alkyl, —CO2R′, aryl or akylaryl, which latter two groups are optionally substituted on the aromatic ring; R′ represent alkyl, aryl or alkaryl; X is halo, H2O, (R′)(R″)SO, R′CO2— or (R′)(R″)C═O, where R″ represents alkyl, aryl or alkaryl; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C′ is C1 to C12 alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1, and A and B are: each independently N-donor nitrile ligands; or B is halo and A is an N-donor pyridine ligand, optionally substituted at one or more of the carbon atoms of the pyridine ring; or p is 0, A is NR7R8 and B is NR9R10, wherein R7, R8, R9 and R10 independently represent H or alkyl, and A and B are linked by an alkylene chain, optionally substituted in or on the alkylene chain, or p is 1, A is NR7 and B is NR9R10, wehrein R7, R9 and R10 are as previously defined, and A and B are linked by an alkylene chain, optionally substituted.
摘要翻译：可用于治疗和/或预防癌症的化合物具有式（I），其中：R 1，R 2，R 3， >，R 4，R 5和R 6独立地表示H，烷基，-CO 2 R'，芳基或烷基芳基，后两个基团任选在芳环上取代; R'代表烷基，芳基或烷芳基; X是卤素，H 2 O，（R'）（R“）SO，R'CO 2 - 或（R'）（R”'）CO，其中R“表示烷基，芳基或烷芳基; Y是反抗; m为0或1; q为1,2或3; C'是C 1至C 12亚烷基，任选在亚烷基链中或在亚烷基链上取代，与两个A基团结合; p为0或1，当p为0时r为1，p为1时r为2，A和B各自为N-供体腈配体; 或B是卤素，并且A是任选在吡啶环的一个或多个碳原子处被取代的N-供体吡啶配体; 或p为0，A为NR 7 R 8，B为NR 9 R 10，其中R' R 8，R 9，R 9和R 10独立地表示H或烷基，并且A和B通过任选在亚烷基链中或亚烷基链上取代的亚烷基链，或p是1，A是NR 7，B是NR 9 R 10，，wehrein R 7，R 9和R 10如前所定义，A和B通过任选取代的亚烷基链连接。

7. 发明授权

US3563678A Pumps 失效
公开(公告)号：US3563678A
公开(公告)日：1971-02-16
申请号：US3563678D
申请日：1969-03-24
申请人： PETER SADLER
发明人： SADLER PETER
IPC分类号： F04C18/332 , F04C23/00 , F04C1/02 , F04C11/00
CPC分类号： F04C18/332 , F04C23/001
摘要： A ROTARY PISTON PUMP, WHEREIN A CIRCULAR PISTON MOVES ORBITALLY WITHIN A CYLINDRICAL PUMPING CHAMBER WITHIN A STATOR WITH INLET AND OUTLET PORTS BEING PROVIDED, ONE TO EACH SIDE OF A PIVOTING VANE COOPERATING WITH BOTH THE STATOR AND THE PISTOR TO FORM A PURTITION IN THE PUMPING CHAMBER, CHARACTERIZED IN THAT THE ROTARY PISTON IS CARRIED BY A ROTARY END DISC ROTATED BY A MAIN SPINDLE AND DEFINING AN END WALL OR PART OF AN END WALL OF THE PUMPING CHAMBER.

8. 发明申请

US20070185315A1 Novel albumins 审中-公开
标题翻译：新的白蛋白
公开(公告)号：US20070185315A1
公开(公告)日：2007-08-09
申请号：US10523312
申请日：2003-07-28
申请人： Stephen Berezenko , Peter Sadler , Alan Stewart , Claudia Blindauer , Kerry Bunyan
发明人： Stephen Berezenko , Peter Sadler , Alan Stewart , Claudia Blindauer , Kerry Bunyan
IPC分类号： A61K38/38 , C07H21/04 , C12P21/06 , C07K14/765
CPC分类号： C07K14/765
摘要： The present invention relates to mutated forms of serum albumin, which display altered metal binding and/or other characteristics with respect to a native albumin from which the mutant has been derived, as well as uses of such mutant albumins in the medical field or in growth of cells in culture.
摘要翻译：本发明涉及突变形式的血清白蛋白，其相对于衍生突变体的天然白蛋白显示改变的金属结合和/或其它特征，以及在医学领域或生长中使用这种突变蛋白的细胞。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式